Kytopen & TQ Therapeutics forge partnership to advance next-generation cell therapies
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
The technology is intended to support imaging-based training, protocol optimisation and surgical planning
The BlueSeal Horizon 3.0T platform incorporates advanced magnet technology
Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
Jaypirca is the first and only FDA-approved non-covalent (reversible) BTK inhibitor
The PCR-based test, delivered via Roche’s cobas liat system, allows results to be obtained during a patient consultation in GP practices and Emergency Rooms
Subscribe To Our Newsletter & Stay Updated